Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Digital transformation to help accelerate drug development and discovery process, says GlobalData

Ever increasing drug discovery and development timelines is a multiscale issue causing delays in patient access to medicines and increasing costs for pharmaceutical companies. Digital transformation could streamline the process, accelerate innovation, and improve efficiency, according to a survey conducted by GlobalData, a leading data and analytics company. In a recent GlobalData’s survey, “Digital Transformation […]
Read more

Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care, says GlobalData

China’s National Medical Products Administration (NMPA) approval of Zai Lab Limited and argenx’s Vyvgart Hytrulo (efgartigimod alfa injection) marks a transformative milestone in chronic inflammatory demyelinating polyneuropathy (CIDP) care, offering the first targeted therapy for this debilitating autoimmune disorder. This approval signals a paradigm shift in CIDP management, underscoring innovation’s role in improving patient outcomes, […]
Read more

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China, says GlobalData

Jiangsu Hansoh Pharmaceutical Group Co Ltd has recently obtained approval for HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC) to be included as Breakthrough-Therapy-Designated (BTD) Drug by the National Medical Products Administration (NMPA) of China for extensive stage small cell lung cancer (ES-SCLC) after standard first-line treatment. Against this backdrop, HS-20093 is expected to strengthen Jiangsu Hansoh […]
Read more

JAK inhibitors redefine atopic dermatitis treatment across 7MM, says GlobalData

The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM). JAK inhibitors represent a breakthrough in addressing inflammatory conditions like AD, providing a targeted approach that enhances treatment efficacy and safety, while promising new therapeutic options for diverse patient […]
Read more

Diagnosed prevalent cases of Parkinson’s disease to reach 3.15 million in 7MM by 2033, forecasts GlobalData

The diagnosed prevalent cases of Parkinson’s disease (PD) in the seven major markets (7MM*) are projected to increase from 2.64 million in 2023 to 3.15 million in 2033, with an annual growth rate (AGR) of 1.94%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, “Parkinson’s Disease Epidemiology Analysis and Forecast to […]
Read more

Paratek Phase IIb results highlight omadacycline’s potential to address unmet needs in NTM treatment, says GlobalData

Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic omadacycline in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. This first-ever, randomized, placebo-controlled trial among the Mycobacterium abscessus complex (MABc) patients, highlights omadacycline’s potential to fulfill a critical unmet need within the NTM market, says GlobalData, a leading […]
Read more

Lack of skills and talent still top hinderance for digital transformation in pharma, says GlobalData

The rapid pace of technological advancement has outstripped the ability of traditional training programs to keep up, creating a significant skills gap. Without the necessary expertise, companies may struggle to integrate new systems, leading to stalled initiatives. Lack of specific skills and talents has been found to be the biggest obstacle for pharmaceutical companies in […]
Read more

UCB and Biogen’s dapirolizumab pegol paves new path for systemic lupus erythematosus treatment, says GlobalData

UCB and Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. With a novel CD40L-targeting mechanism and favorable efficacy outcomes, this therapy has the potential to challenge established SLE treatments […]
Read more

Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents, says GlobalData

Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs). With current treatments largely focused on motor symptoms, the pipeline across the seven major markets (7MM*) highlights a growing emphasis on DMTs and non-motor symptom therapies, signaling a commitment to advancing PD treatments that address the full […]
Read more

Donald Trump’s return sparks uncertainty for US pharma and healthcare industries, says GlobalData

Donald Trump’s return to the White House brings renewed uncertainty to the US pharmaceutical and healthcare industries, with potential shifts in policies affecting millions. His possible repeal or restructuring of the Affordable Care Act (ACA), coupled with plans to appoint anti-vaccine advocate Robert F. Kennedy Jr. to a prominent healthcare role, raises concerns over public […]
Read more

Roche will aim to tackle gene therapy challenges through Dyno Therapeutics collaboration, says GlobalData

Dyno Therapeutics has recently announced the formation of a new strategic partnership with Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. The partnership will see the utilization of artificial intelligence (AI), which is a key industry trend in the development of gene therapies in neurological disorders and could improve the […]
Read more

Egypt marks major achievement with malaria-free certification, but need for global R&D remains significant, says GlobalData

The World Health Organization (WHO) has certified Egypt as being malaria-free, following a near 100-year endeavour by the Egyptian government. Egypt is the third country to be declared malaria-free in the WHO Eastern Mediterranean Region, and the 44th country globally. However, hundreds of millions of cases of malaria are still reported worldwide each year. These […]
Read more

Asthma crisis in US marginalized communities from redlining requires more than just healthcare interventions, says GlobalData

Decades after the discriminatory practice of redlining was banned in the US, its lasting impact is still driving significant health disparities, particularly in asthma prevalence, according to recent studies. These findings highlight how the combination of poor housing conditions and environmental pollutants in historically redlined neighborhoods continues to fuel the asthma crisis, particularly among children. […]
Read more

World Osteoporosis Day highlights need for comprehensive care strategies, says GlobalData

Marking World Osteoporosis Day on 20 October, the International Osteoporosis Foundation (IOF) brought worldwide attention to a crucial issue: the urgent need for robust osteoporosis screening and sustained care strategies to prevent fragility fractures. Under the theme “Say No to Fragile Bones,” it highlighted the gaps in diagnosis and treatment, stressing the importance of proactive […]
Read more

Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection, says GlobalData

Australia’s Therapeutic Goods Administration (TGA) has recently decided not to register lecanemab (Leqembi) for patients with mild cognitive impairment (MCI) or mild dementia of Alzheimer’s disease (AD). Despite lecanemab demonstrating slowing of disease progression in pivotal trials, concerns about its safety profile have led to TGA’s decision. Against this backdrop, Eli Lilly’s donanemab that has been […]
Read more
1 … 14 15 16 17 18 … 110